Abstract library

16 results for "I Dali".
#3035 Large-Cell Neuroendocrine Carcinoma of the Lung in Elderly Patient: Case Report and Review of Literature
Introduction: Lung neuroendocrine tumors account for less than 25% of lung cancers.Which is a rare malignant tumor with an aggressive profile has often already affected lymph nodes at presentation and it is de novo metastatic in nearly 40% of cases.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Hanane Aliane
Authors: Aliane H, Ghomari S
#116 Transarterial chemoembolization (TACE) of liver metastasis from pancreatic well-differentiated endocrine carcinoma
Introduction: The behavior of liver metastasis from endocrine pancreatic carcinoma is eterogeneous, and several treatments have been proposed, but no single option is ideal.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD Vanessa Capitanio
Authors: Capitanio V, Papa M, Zerbi A, Vitali G, ...
#120 Somatostatin receptors 1-5 expression in a large series of well-differentiated neuroendocrine tumors
Introduction: For their antisecretive and antiproliferative effect somatostatin analogs (SA) have been used in the treatment of neuroendocrine tumors (NETs), based on the expression of somatostatin receptors (sstRs). The potential availability of new SA for the treatment of patients with NETs suggests a better characterization of sstRs.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Paola Loli
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#159 Detection of cardiac metastases in patients with neuroendocrine tumors: comparison of Ga-68 DOTA-SMS-R PET/CT, cardiac MRI, CT scan and 2D echocardiography
Introduction: Neuroendocrine tumor metastases to the heart have been sparsely reported in literature. There is as of yet no detailed study on the best imaging method for the detection of this rare site of metastases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Ali S, Secknus M A, Lauer B, ...
#894 The Effects of cAMP in Different Neuroendocrine Tumorous Cells: The Role of Epac and PKA in Cell Proliferation and Cell Adhesion
Introduction: cAMP is implicated in the inhibition or stimulation of proliferation depending on cell type. Although the effects exerted by cAMP were initially attributed to the PKA activation, two cAMP-activated guanine nucleotide exchange (Epac1/2) have been later identified as cAMP targets.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Eleonora Vitali
Keywords: cAMP, PKA, EPAC, GEP-NET
#917 The Second Non-Metastatic Tumor in Romanian Patients with NETs
Introduction: NETs involve aggressive evolution as progression of primary tumor. Some cases associate a second apparently non-related tumor.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Mara Carsote
#981 Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Clinical Features, Diagnosis, Management, and Long-Term Follow-Up
Introduction: There are a few large series of patients with parathyroid hormone (PTH)-related protein (PTHrP) secreting neuroendocrine tumors (NETs) causing severe hypercalcemia.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: Drs Kimberly Kamp
Keywords: PTH, PTHrP, net, hypercalcemia
#1075 Filamin-A Is Required for Somatostatin Receptor 2 (SST2) Stabilization, Signaling and Angiogenesis Regulation in Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Somatostatin receptor type 2 (SST2) is the main pharmacological target for GEP-NETs. A subset of patients is resistant to somatostatin analogs (SSa), although the molecular mechanisms responsible for resistance are poorly understood. Several studies identified cytoskeleton protein as determinant in receptor anchoring and signaling
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Eleonora Vitali
Keywords: FLNA, SST2, GEP-NET
#1455 Expression of Mutated p53 Protein in Gastroenteropancreatic Neuroendocrine Carcinoma (WHO G3)
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, highly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short-lasting.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: PhD student Abeir Ali